Cite
Ellis PM, Morzycki W, Melosky B, et al. The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. Curr Oncol. 2009;16(1):27-48doi: 10.3747/co.v16i1.393.
Ellis, P. M., Morzycki, W., Melosky, B., Butts, C., Hirsh, V., Krasnoshtein, F., Murray, N., Shepherd, F. A., Soulieres, D., Tsao, M. S., & Goss, G. (2009). The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. Current oncology (Toronto, Ont.), 16(1), 27-48. https://doi.org/10.3747/co.v16i1.393
Ellis, P M, et al. "The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement." Current oncology (Toronto, Ont.) vol. 16,1 (2009): 27-48. doi: https://doi.org/10.3747/co.v16i1.393
Ellis PM, Morzycki W, Melosky B, Butts C, Hirsh V, Krasnoshtein F, Murray N, Shepherd FA, Soulieres D, Tsao MS, Goss G. The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. Curr Oncol. 2009 Jan;16(1):27-48. doi: 10.3747/co.v16i1.393. PMID: 19229369; PMCID: PMC2644627.
Copy
Download .nbib